Results 231 to 240 of about 101,700 (245)

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

New England Journal of Medicine, 2006
Brian J Druker, François Guilhot, Hagop M Kantarjian   +2 more
exaly  

Imatinib

Reactions Weekly, 2015
openaire   +2 more sources

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Nature Medicine, 2006
Risto Kerkelä, Anthony Rosenzweig, Richard A Van Etten   +2 more
exaly  

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Lancet, The, 2006
George D Demetri, Jaap Verweij, Grant Mcarthur   +2 more
exaly  

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

New England Journal of Medicine, 2006
Hagop M Kantarjian, Francis J Giles, Kapil N Bhalla   +2 more
exaly  

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Nature Medicine, 2011
Michael J Cavnar, Charlotte Ariyan, Tianhua Guo   +2 more
exaly  

Curing CML with imatinib—a dream come true?

Nature Reviews Clinical Oncology, 2011
Michael Deininger
exaly  

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

New England Journal of Medicine, 2002
Hagop M Kantarjian, Charles L Sawyers, Andreas Hochhaus   +2 more
exaly  

Imatinib

Reactions Weekly, 2019
openaire   +2 more sources

Imatinib

Reactions Weekly, 2012
openaire   +1 more source